Haptoglobin (HP) is an abundant plasma protein with primary function in hemoglobin scavenging and detoxification. HP binds free hemoglobin with high affinity during hemolysis, forming the Hb-HP complex that reduces heme's oxidative properties and facilitates recognition by macrophage scavenger receptor CD163, leading to hemoglobin catabolism via heme oxygenase and biliverdin reductase 1. Beyond hemoglobin binding, HP possesses anti-inflammatory and immune-modulatory functions 2. Recent findings reveal that fucosylated HP (Fu-HP) promotes inflammatory responses in sepsis by interacting with Mincle, a C-type lectin receptor, amplifying NLRP3 inflammasome activation and cytokine production 3. HP phenotypes correlate with disease susceptibility and longevity, with the HP*1/*1 genotype associated with increased probability of reaching advanced age, while HP*2 allele carriers show disadvantage in aging 2. Clinically, HP variants are relevant to hemolytic diseases including sickle cell disease and hemoglobinopathies, where therapeutic derivatives may prevent hemoglobin toxicity 1. HP also demonstrates involvement in sepsis prognosis, with fucosylation patterns correlating with inflammatory markers and sepsis severity. Understanding HP's structural biology and glycosylation modifications offers potential therapeutic targets for managing hemolytic and inflammatory conditions.